Eli Lilly & Co. is making a substantial $4.5 billion investment to establish the Lilly Medicine Foundry in Lebanon, Indiana, a first-of-its-kind facility that will integrate advanced manufacturing and drug development. Scheduled to open in late 2027, the Foundry aims to accelerate the company's drug pipeline, particularly focusing on molecular therapies and scaling up medicines for clinical trials. This initiative is part of Lilly's broader strategy to maintain its competitive edge in the pharmaceutical industry, especially following the success of its obesity drugs Mounjaro and Zepbound. The facility will increase Lilly's total U.S. capital commitment to over $23 billion since 2020 and is expected to create 400 highly skilled jobs. Additionally, this investment adds to Lilly's extensive commitments in the state, including previous multi-billion dollar investments to enhance its manufacturing capabilities.